FDA Panel Supports RP1 Evidence in Advanced Melanoma

Company Replimune Event Type Regulatory (Advisory Committee Vote) Modality Oncolytic herpes simplex virus type 1 plus anti-PD-1 antibody Asset RP1 (vusolimogene oderparepvec) plus nivolumab Target Tumor-selective viral lysis with GM-CSF and GALV-GP-R- fusogenic protein expression; PD-1 Disease Area Advanced melanoma previously treated with an anti-PD-1…